Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Acrivon Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/23/2023 |
4
| Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 493,994 shares
@ $0 |
|
| 06/28/2023 |
4
| BAUM CHARLES M (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 32,500 options to buy
@ $12.88, valued at
$418.6k
|
|
| 06/28/2023 |
4
| Chione Ltd (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Sold 16 shares
@ $12.93, valued at
$206.9 |
|
| 06/06/2023 |
4
| Devroe Eric (COO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Exercised 9,225 options to buy
@ $1.04, valued at
$9.6k
|
|
| 06/01/2023 |
4
| Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Exercised 33,605 options to buy
@ $3.88, valued at
$130.4k
|
|
| 11/21/2022 |
4
| Chione Ltd (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Bought 400,000 shares
@ $12.5, valued at
$5M
Converted 3,445,940 shares
@ $0
Converted 10,657 shares
@ $0
Converted 8,497,692 preferred shares
@ $0
Converted 26,281 preferred shares
@ $0 |
|
| 11/21/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Converted 994,706 shares
@ $0
Bought 3,389,500 shares
@ $12.5, valued at
$42.4M
Converted 426,302 shares
@ $0
Converted 2,452,947 preferred shares
@ $0
Converted 1,051,263 preferred shares
@ $0 |
|
| 11/21/2022 |
4
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Converted 888,130 shares
@ $0
Converted 2,190,131 preferred shares
@ $0 |
|
| 11/16/2022 |
4
| DiRocco Derek (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 35,235 options to buy
@ $12.5, valued at
$440.4k
|
|
| 11/16/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 35,235 options to buy
@ $12.5, valued at
$440.4k
|
|
| 11/16/2022 |
4
| Shacham Sharon (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 35,235 options to buy
@ $12.5, valued at
$440.4k
|
|
| 11/16/2022 |
4
| TOMSICEK MICHAEL JOHN (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 35,235 options to buy
@ $12.5, valued at
$440.4k
|
|
| 11/16/2022 |
4
| Gamelin Erick (Chief Medical Officer) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 20,030 shares
@ $0
Granted 60,090 options to buy
@ $12.5, valued at
$751.1k
|
|
| 11/16/2022 |
4
| Devroe Eric (COO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 33,383 shares
@ $0
Granted 100,150 options to buy
@ $12.5, valued at
$1.3M
|
|
| 11/16/2022 |
4
| Holm-Jorgensen Rasmus (CFO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 20,030 shares
@ $0
Granted 60,090 options to buy
@ $12.5, valued at
$751.1k
|
|
| 11/16/2022 |
4
| Masson Kristina (EVP - Business Operations) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 26,707 shares
@ $0
Granted 934,731 shares
@ $0
Granted 503,419 shares
@ $0
Granted 60,090 shares
@ $0
Granted 80,120 options to buy
@ $12.5, valued at
$1M
Granted 180,269 options to buy
@ $12.5, valued at
$2.3M
|
|
| 11/16/2022 |
4
| Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 934,731 shares
@ $0
Granted 503,419 shares
@ $0
Granted 60,090 shares
@ $0
Granted 26,707 shares
@ $0
Granted 180,269 options to buy
@ $12.5, valued at
$2.3M
Granted 80,120 options to buy
@ $12.5, valued at
$1M
|
|
|
|